In this session, we will present the latest findings and progress from ALS clinical research studies conducted by NEALS Affiliated Trials aimed at advancing our understanding, treatment, and eventual cure of ALS. This session offers a valuable opportunity to stay informed about critical advancements in ALS research.

10:55 Results and Learnings From the Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)

Sabrina Paganoni, MD, PhD (Healey & AMG Center for ALS at Mass General)

Leonard van den Berg, MD, PhD (University Medical Center Utrecht)

11:05 HIMALAYA trial: Double-blind, placebo-controlled trial of RIPK1

inhibitor (SAR443820) in ALS

Nazem Atassi, MD, MBA (Sanofi)

Merit Cudkowicz, MD, MSc (Healey & AMG Center for ALS at Mass General)

11:15 ALL ALS: Year 1 Progress and Future Enrollment Goals

James Berry, MD, MPH (Healey & AMG Center for ALS at Mass General)

Robert Bowser, PhD (Barrow Neurological Institute)

11:25 HEALEY Platform Trial updates what's new for 2025

Merit Cudkowicz, MD, MSc (Healey & AMG Center for ALS at Mass General)

11:35 A Phase 2A Study of TPN-101, A Nucleoside Reverse Transcriptase

Inhibitor, in Patients with C9ORF72-Related ALS/FTD

Andrew Satlin, MD (Transposon Therapeutics)

11:45 Pioneering Progress: Exciting Updates from NEALS-Affiliated Trials

Jinsy Andrews, MD, MSc (NEALS Co-Chair; Columbia University)

ALS Association

ALS Hope Foundation

Sean M. Healey & AMG Center for ALS at Mass General

Tambourine